| Study (author, year) | Overall incidence | Drug-related | No. discontinued | ||||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||
| F | NF | F | NF | F | NF | ||
| Travoprost/Timolol (Hughes, 2005) | 44 (27.3) | 55 (35.5) | Approx.5% | Approx.5% | |||
| Latanoprost/Timolol (Diestelhorst, 2006) | 44 (16.8) | 62 (24.4) | 21 (8.0) | 33 (13.0) | 6 (2.3) | 7 (2.8) | |
| Brimonide tartrate/Timolol (Goni, 2005) | 56 (30.3) | 45 (24.6) | 38 (20.2) | 26 (14.2) | 4 (2.1) | 2 (1.1) | |
| Brimonidine tartrate/Timolol (Konstas, 2007) | 8 (28.5) | 12 (42.8) | 4 (12.5) | 3 (9.3) | |||
| Travoprost/Timolol (Schuman, 2005) | 25.4 | 34.4 | 8 (5.0) | 4 (2.5) | |||
| Dorzolamide/Timolol (Hutzelmann, 1998) | 72 (47.6) | 76 (51.3) | 36 (23.8) | 43 (29.0) | 2 (1.0) | 1 (1.0) | |
| Dorzolamide/Timolol (Strohmaier, 1998) | 41 (34.0) | 31 (26.0) | 12 (10.0) | 12 (10.0) | 7 (6.0) | 3 (2.0) | |
F, fixed combination; NF, non-fixed combination.